PROEHL GERALD T

Insider Reports History

Location
San Diego, CA
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Transaction view
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by PROEHL GERALD T:

Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Common Stock
Shares / value
122,563
Estimated value
$371,365
Report date
23 Dec 2025
Price
$3.03
Ownership
By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Form 4 holding Director

TENAX THERAPEUTICS, INC.

Security class
Pre-Funded Warrant
Shares / value
31,654
Estimated value
$284,886
Report date
09 Jan 2026
Price
$9.00
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,654
Form 4 holding Director

TENAX THERAPEUTICS, INC.

Security class
Stock Option (right to buy)
Shares / value
30,000
Estimated value
$270,000
Report date
09 Jan 2026
Price
$9.00
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Common Stock
Shares / value
79,795
Estimated value
$241,778
Report date
23 Dec 2025
Price
$3.03
Ownership
By Proehl Investment Ventures LLC
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Common Stock
Shares / value
7
Estimated value
$21
Report date
23 Dec 2025
Price
$3.03
Ownership
By Allison Taylor Proehl 2020 Irrevocable Trust
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Common Stock
Shares / value
3
Estimated value
$9
Report date
23 Dec 2025
Price
$3.03
Ownership
By Meghan Proehl Wilder 2020 Irrevocable Trust
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Warrant (Right to Buy)
Shares / value
787,402
Estimated value
Report date
21 Jan 2025
Price
Ownership
By Proehl Investment Ventures LLC
Underlying class
Common Stock
Underlying amount
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Series C Warrant (Right to Buy)
Shares / value
490,496
Estimated value
Report date
23 Dec 2025
Price
Ownership
By Proehl Family Trust
Underlying class
Common Stock
Underlying amount
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Series D Warrant (Right to Buy)
Shares / value
490,496
Estimated value
Report date
23 Dec 2025
Price
Ownership
By Proehl Family Trust
Underlying class
Common Stock
Underlying amount
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Series C Warrant (Right to Buy)
Shares / value
122,549
Estimated value
Report date
23 Dec 2025
Price
Ownership
By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Underlying class
Common Stock
Underlying amount
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Series D Warrant (Right to Buy)
Shares / value
122,549
Estimated value
Report date
23 Dec 2025
Price
Ownership
By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Underlying class
Common Stock
Underlying amount
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Warrant (Right to Buy)
Shares / value
78,740
Estimated value
Report date
23 Dec 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President, CEO and Chairman, Director, 10%+ Owner

Dermata Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
37,500
Estimated value
Report date
02 Jan 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by PROEHL GERALD T

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .